252 related articles for article (PubMed ID: 29775157)
1. Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.
Duffy MJ; McDermott EW; Crown J
Tumour Biol; 2018 May; 40(5):1010428318776169. PubMed ID: 29775157
[TBL] [Abstract][Full Text] [Related]
2. [Circulating proteinic biomarkers and breast cancer].
Mathelin C; Koehl C; Rio MC
Gynecol Obstet Fertil; 2006; 34(7-8):638-46. PubMed ID: 16876456
[TBL] [Abstract][Full Text] [Related]
3. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
[TBL] [Abstract][Full Text] [Related]
4. Role of tumor markers and circulating tumors cells in the management of breast cancer.
Saad A; Abraham J
Oncology (Williston Park); 2008 Jun; 22(7):726-31; discussion 734, 739, 743-4. PubMed ID: 18619119
[TBL] [Abstract][Full Text] [Related]
5. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
[TBL] [Abstract][Full Text] [Related]
6. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
7. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
8. Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy.
Lehner J; Stötzer OJ; Fersching D; Nagel D; Holdenrieder S
Clin Chim Acta; 2013 Oct; 425():206-11. PubMed ID: 23916787
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
Duffy MJ; Walsh S; McDermott EW; Crown J
Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
[TBL] [Abstract][Full Text] [Related]
10. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour markers in breast cancer.
Seregni E; Coli A; Mazzucca N;
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S15-22. PubMed ID: 15127239
[TBL] [Abstract][Full Text] [Related]
12. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
[TBL] [Abstract][Full Text] [Related]
13. Use of serum tumor markers for the diagnosis and follow-up of breast cancer.
Barrenetxea G; Schneider J; Llorente MF
Oncology; 1998; 55(5):447-9. PubMed ID: 9732223
[No Abstract] [Full Text] [Related]
14. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
Clin Chem; 1996 Apr; 42(4):564-75. PubMed ID: 8605674
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers in the treatment of cancer: opportunities and pitfalls.
Melichar B
Clin Chem Lab Med; 2013 Jul; 51(7):1329-33. PubMed ID: 23729626
[No Abstract] [Full Text] [Related]
16. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor markers in breast cancer: accepted utilities and novel prospects.
Stearns V; Yamauchi H; Hayes DF
Breast Cancer Res Treat; 1998; 52(1-3):239-59. PubMed ID: 10066086
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
20. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]